Die Onkologie pp 1629-1651 | Cite as

Apudome: Neuroendokrine Tumoren des Gastrointestinaltrakts

  • R. Arnold
  • B. Simon
  • R. Göke

Zusammenfassung

Für die Nomenklatur der endokrinen Tumoren des Gastrointestinaltrakts werden die in der Übersicht zusammengefassten Begriffe synonym verwendet. Der Terminus „Karzinoid“ ist streng genommen den endokrinen Tumoren des Magen-Darm-Trakts (Vorder-, Mittel- und Hinterdarm) und den sich aus dem Vorderdarm abgeleiteten Organsystemen wie dem Bronchialsystem vorbehalten (⊡ Tabelle 67.1; Arnold 1997). Endokrine Pankreastumoren fallen danach nicht unter den Karzinoidbegriff, da diese sich aus den Langerhans-Inseln und nicht aus dem diffusen endokrinen Zellsystem des Gastrointestinaltrakts entwickeln. Zumindest bei Vertebraten entstehen die Langerhans-Inseln aus einem eigenständigen Inselorgan, das während der Ontogenese mit dem exokrinen Pankreasanteil verschmilzt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Agarwal SK, Guru SC, Heppner et al. (1999) Menin interacts with the AP1 transcription factor Jun D and represses Jun D activated transcription. Cell 96: 143–152PubMedCrossRefGoogle Scholar
  2. Ahlman H (1997) Management of neuroendocrine tumours: current surgical standards. J Endocrinol Invest 20: 56–58Google Scholar
  3. Airaksinen MS, Titievsky A, Saarma M (1999) GDNF family neurotrophic factor signaling: four masters, one servant? Molecular and Cellular Neuro sciences 13: 313–325CrossRefGoogle Scholar
  4. Anthuber M, Jauch KW, Briegel J et al. (1996) Results of liver transplantation for gastroenteropancreatic tumor metastases. World J Surg 20: 73–76PubMedCrossRefGoogle Scholar
  5. Arnold R (1997) Das Karzinoid — eine in Frage gestellte Entität? Chirurg 1: 132–135CrossRefGoogle Scholar
  6. Arnold R, Frank M (1996) Gastrointestinal endocrine tumours: medical management. In: O’Shea D, Bloom SR (eds), Bailliere’s clinical gastroenterology. Gastrointestinal endocrine tumours, vol 10, no 4. Bailliere Tindall, London Philadelphia Sydney Tokyo TorontoGoogle Scholar
  7. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C et al. (1996) Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38: 430–438PubMedCrossRefGoogle Scholar
  8. Ashcroft FM (1996) Sweet news for hypoglycemic babies. Nature Med 2: 1301–1302PubMedCrossRefGoogle Scholar
  9. Bartz C, Ziske C, Wiedenmann B, Moelling K (1996) P53 tumour suppressor gene expression in pancreatic neuroendocrine tumour cells. Gut 38: 403–409PubMedCrossRefGoogle Scholar
  10. Beghelli S, Pelosi G, Zamboni G, Falconi M, Iacono C, Bordi C, Scarpa A (1998) Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p. J Pathol 186: 41–50PubMedCrossRefGoogle Scholar
  11. Calender A (2000) Molecular genetics of neuroendocrine tumors. Digestion 62 [Suppl 1]: 3–18PubMedCrossRefGoogle Scholar
  12. Capella C, Heitz PU, Höfler H, Solcia E, Klöppel G (1995) Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Virchows Arch 425: 547–560PubMedCrossRefGoogle Scholar
  13. Chandrasekharappa SC, Guru SC, Manickam P et al. (1997) Positional cloning of the gene for multiple endocrine neoplasia type I. Science 276: 404–407PubMedCrossRefGoogle Scholar
  14. Clouse ME, Perry L, Stuart K, Stokes KR (1994) Hepatic arterial chemoembolization for metastatic endocrine tumours. Digestion 55 [Suppl 3]: 92–97PubMedCrossRefGoogle Scholar
  15. Creutzfeldt W, Arnold R, Creutzfeldt C, Deuticke U, Frerichs H, Track NS (1973) Biochemical and morphological investigations of 30 insulinomas. Diabetologia 9: 217–231PubMedCrossRefGoogle Scholar
  16. Creutzfeldt W, Arnold R, Creutzfeldt C, Track NS (1975) Pathomorphologic, biochemical and diagnostic aspects of gastrinoma (Zollinger-Ellison syndrome). Human Pathology 6: 47–76PubMedCrossRefGoogle Scholar
  17. Cupisti K, Hoppner W, Dotzenrath C, Simon D, Berndt I, Roher HD, Goretzki PE (2000) Lack of MEN1 gene mutations in 27 sporadic insulinomas. Eur J Clin Invest 30: 325–329PubMedCrossRefGoogle Scholar
  18. Curtiss SI, Mor E, Schwartz ME et al. (1995) A rational approach to the use of hepatic transplantation in the treatment of metastatic neuroendocrine tumors. J Am Coll Surg 180: 184–187PubMedGoogle Scholar
  19. Debelenko LV, Brambilla E, Agarwal SK et al. (1997a) Identification of MEN 1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet 6: 2285–2290PubMedCrossRefGoogle Scholar
  20. Debelenko LV, Emmert-Buck MR, Zhuang Z et al. (1997b) The multiple endocrine neoplasia type I gene locus is involved in the pathogenesis of type Il gastric carcinoids. Gastroenterology 113: 773–781PubMedCrossRefGoogle Scholar
  21. Debelenko LV, Zhuang Z, Emmert-Buck MR et al. (1997c) Allelic deletions on chromosome 11q13 in multiple endocrine neoplasm type 1-associated and sporadic gastrinomas and pancreatic endocrine tumors. Cancer Res 57: 2238–2243PubMedGoogle Scholar
  22. Delamarre-van de Waal HA, Veldcamp EJM, Schrander-Strumpel CTRM (1987) Long-term management of nesidioblastosis using the somatostatin analogue SMS 201–995. N Engl J Med 316: 222–223CrossRefGoogle Scholar
  23. Di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnagh C, Somma L, Zilembo N, di Leo (1996) Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77: 402–408PubMedCrossRefGoogle Scholar
  24. Donis-Keller H, Dou S, Chi D et al. (1993) Mutations in the RET proto-onocogene are associated with MEN2A and FMTC. Hum Mol Genet 2: 851–856PubMedCrossRefGoogle Scholar
  25. Dunne MJ, Kane C, Shepherd RM et aí. (1997) Familial persistent hyperinsulinemic hypoglycemia of infancy and mutations in the sulfonylurea receptor. N Engl J Med 336: 703–706PubMedCrossRefGoogle Scholar
  26. Fajans SS, Floyd JC, Thiffault CA (1968) Further studies on diazoxide suppression of insulin release from abnormal and normal islet tissue in man. Ann New York Acad Science 150: 26–80Google Scholar
  27. Frank-Raue K, Höppner W, Frilling A et al. (1996) Mutations of the ret protonococene in German multiple endocrine neoplasia families: relation between genotype and phenotype. J Clin Endocrinol Metab 81: 1780–1783PubMedCrossRefGoogle Scholar
  28. Fuji T, Kawai T, Saito K et al. (1999) MEN 1 gene mutations in sporadic neu- roendocrine tumors of foregut derivation. Pathol Int 49: 968–973CrossRefGoogle Scholar
  29. Godwin JD (1975) Carcinoid tumors: an analysis of 2837 cases. Cancer 36: 560–569PubMedCrossRefGoogle Scholar
  30. Görtz B, Roth J, Krähenmann A et al. (1999) Mutations and allelic deletions of the MEN 1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms. Am J Pathol 154: 429–436PubMedCrossRefGoogle Scholar
  31. Grant CS (1996) Insulinoma. In: O’Shea D, Bloom SR (eds), Bailliere’s clinical gastroenterology. Gastrointestinal endocrine tumours, vol 10, no 4. Bailliere Tindall, London Philadelphia Sydney Tokyo TorontoGoogle Scholar
  32. Gumbs AA, Moore PS, Falconi M, Bassi C, Beghelli S, Modlin I, Scarpa A (2002) Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms. J Surg Oncol 81: 45–53PubMedCrossRefGoogle Scholar
  33. Hessman O, Lindberg D, Einarsson A et al. (1999) Genetic alterations on 3p, 11g13, and 18q in nonfamilial and MEN 1-associated pancreatic endocrine tumors. Genes, Chromosomes Cancer 26: 258–264PubMedCrossRefGoogle Scholar
  34. Hessmann O, Lindberg D, Skogseid B et al. (1998) Mutation of the multiple endocrine neoplasia type 1 gene in non-familial, malignant tumors of the endocrine pancreas. Cancer Res 58: 377–379Google Scholar
  35. Heppner C, Kester MB, Agarwal SK et al. (1997) Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet 16: 375–378PubMedCrossRefGoogle Scholar
  36. Higham DA, Bishop LA, Dimaline R et al. (1999) Mutations of Regia are associated with enterochromaffin-like cell tumor development in patients with hypergastrinemia. Gastroenterology 116: 1310–1318PubMedCrossRefGoogle Scholar
  37. Hofstra RMW, Landsvater RM, Ceccherini I et aí. (1994) A mutation in the RET protooncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367: 375–376PubMedCrossRefGoogle Scholar
  38. Jensen RT (1996) Gastrinoma. In: O’Shea D, Bloom SR (eds), Bailliere’s clinical gastroenterology. Gastrointestinal endocrine tumours, vol 10, no 4. Bailliere Tindall, London Philadelphia Sydney Tokyo TorontoGoogle Scholar
  39. Jensen RT, Norton JA (1995) Endocrine neoplasms of the pancreas. In: Yamada T, Alpers DH, Owyang C, Powell DW, Silverstein FE (eds), Textbook of gastroenterology. Lippincott, Philadelphia, pp 2131–2160Google Scholar
  40. Joseph K, Stapp J, Reinecke J et al. (1992) Rezeptorszintigraphie bei endokrinen gastroenteropankreatischen Tumoren. Dt Med Wschr 117: 1025–1028CrossRefGoogle Scholar
  41. Kane C, Shepherd RM, Squires PE et al. (1996) Loss of functional KATP channels in pancreatic beta-cells causes persistent hyperinsulinemic hypoglycemia of infancy. Nat Med 2: 1344–1347PubMedCrossRefGoogle Scholar
  42. Kim YS, Burns AL, Goldsmith PKet al. (1999) Stable overexpression of MEN1 suppresses tumorigenicity of RAS. Oncogene 18(43): 5936–42Google Scholar
  43. Krenning EP, Kwekkeboom DJ, Bakker WH et al. (1993) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [1231-Tyr3]octreotide: The Rotterdam experience with more than 1, 000 patients. Eur J Nucl Med 20: 716–31PubMedCrossRefGoogle Scholar
  44. Kubota A, Yamada Y, Kagimoto S et al. (1994) Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201–995 in treatment of human endocrine tumors. J Clin Invest 93: 1321–1325PubMedCrossRefGoogle Scholar
  45. Lohmann DR, Funk A, Niedermeyer HP, Haupel S, Hofler H (1993) Identification of p53 gene mutations in gastrointestinal and pancreatic carcinoids by nonradioisotopic SSCA. Virchows Archiv. B, Cell Pathology Including Molecular Pathology 64: 293–296Google Scholar
  46. Lonlay-Debeney P, Poggi-Travert F, Fournet JC et al. (1999) Clinical features of 52 neonates with hyperinsulinism. N Eng J Med 340: 1169–75CrossRefGoogle Scholar
  47. Marsh HM, Martin BS, Kvols LK, Gracey DR, Warner MA, Warner ME, Moertel CG (1987) Carcinoid crisis during anesthesia: Successful treatment with a somatostatin analogue. Anesthesiology 66: 89–91PubMedCrossRefGoogle Scholar
  48. Maton PN, Vinayek R, Frucht H et al. (1986) Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology 97: 827–836Google Scholar
  49. Metz DC, Jensen RT (1995) Advances in gastric antisecretory therapy in Zollinger-Ellison-Syndrome. In Mignon M, Jensen RT (eds), Endocrine tumours of the pancreas. Recent advances in research and management. Frontiers of Gastrointestinal Research. Basel, Karger, pp 240–257Google Scholar
  50. Metz DC, Pisegna JR, Fischbeyn VA, Benya RV, Jensen RT (1992) Current maintenance doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 103: 1498–1508PubMedGoogle Scholar
  51. Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13, 715 carcinoid tumors. Cancer 97: 934–959PubMedCrossRefGoogle Scholar
  52. Moertel CG, Kvols LK, O’Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68: 227–232PubMedCrossRefGoogle Scholar
  53. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozotocin-doxorubicin, streptozotocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326: 519–523PubMedCrossRefGoogle Scholar
  54. Moore PS, Orlandini S, Zamboni G et al. (2001) Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Brit J Cancer 84: 253–262PubMedCrossRefGoogle Scholar
  55. Mulligan LM, Kwok JBJ, Healey CS et al. (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia typa 2A. Nature (London) 363: 458–460CrossRefGoogle Scholar
  56. Muscarella P, Melvin WS, Fisher WE et al. (1998) Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene activation. Cancer Res 58: 237–240PubMedGoogle Scholar
  57. Nauck MA, Baum F, Seidensticker F, Michael Roder, Dinesen B, Creutzfeldt W (1997) A hyperinsulinaemic, sequentially eu- and hypoglycaemic clamp test to characterize autonomous insulin secretion in patients with insulinoma. EurJ Clin Invest 27: 109–115CrossRefGoogle Scholar
  58. Nikiforova MN, Nikiforov YE, Biddinger P et al. (1995) Frequent loss of heterozygosity at chromosome 3p14. 2–3P21 in human pancreatic islet cell tumors. Clin Endocrinol 51: 27–33CrossRefGoogle Scholar
  59. Öberg K (1997) Biological treatment of malignant neuroendocrine tumors. Endocrinol Invest 20: 62–64Google Scholar
  60. Oberndorfer S (1907) Karzinoide Tumoren des Dünndarms. Frankfurt Z Pathol 1: 426–429Google Scholar
  61. Ohiwa M, Murakami H, Iwashita T et al. (1997) Characterization of Ret-ShcGrb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations. Biochem Biophys Res Commun 237: 747–751PubMedCrossRefGoogle Scholar
  62. Pavelic K, Hrascan R, Kapitanovic S et al. (1996) Molecular genetics of malignant insulinoma. Anticancer Res 16: 1707–1717PubMedGoogle Scholar
  63. Pfarr CM, Mechta F, Spyrou G, Lallemand D, Carillo S, Yaniv M (1994) Mouse JunD negatively regulates fibroblast growth and antagonizes transformation by ras. Cel l 76: 747–760CrossRefGoogle Scholar
  64. Pearse AGE (1969) The cytochemistry and ultrastructure of polypeptide hormone producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem 17: 303–313PubMedCrossRefGoogle Scholar
  65. Reubi JL, Häcki WH, Lamberts SWJ (1987) Hormone-producing gastrointestinal tumours contain a high density of somatostatin receptors. J Clin Endocrinol Metab 65: 1127–1134PubMedCrossRefGoogle Scholar
  66. Rindi G, Luinetti O, Comaggia M, Capella C, Solcia E (1993) Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 104: 994–1006PubMedGoogle Scholar
  67. Rindi G, VillanacciV, Ubiali A (2000) Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors. Digestion 62 [Suppl 1]: 19–26PubMedCrossRefGoogle Scholar
  68. Rösch T, Lightdale CJ, Botet JF et al. (1992) Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 26: 1721–1726CrossRefGoogle Scholar
  69. Ruszniewski P, Rougier P, Roche A et al. (1993) Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors: a prospective phase II study in 24 patients. Cancer 71: 2624–2630PubMedCrossRefGoogle Scholar
  70. Ruszniewski P, Ducreux M, Chayvialle JA et al. (1996) Treatment of the carcinoid syndrome with the long-acting somatostatin analogue Ianreotide: a prospective study in 39 patients. Gut 39: 279–283PubMedCrossRefGoogle Scholar
  71. Saltz L, Trochanowsky G, Buckley M, Heffernan B, Niedzwicki D, TaoY, Kelsen D (1993) Octeotide as an antineoplastic agent in the treatment of functional and non-functional neuroendocrine tumors. Cancer 72: 244–248PubMedCrossRefGoogle Scholar
  72. Sawicki MP, Wan Y-JY, Johnson CL, Berenson J, Gatti RA, Passaro E Jr (1992) Loss of heterozygosity on chromosome 11 in sporadic gastrinomas. Hum Genet 89: 445–449PubMedCrossRefGoogle Scholar
  73. Sempoux C, GuiotY, Dubois D, Nollevaux MC, Saudubray JM, Nihoul-Fekete C, Rahier J (1998) Pancreatic B-cell proliferation in persistent hyperinsulinemic hypoglycemia of infancy: an immunohistochemical study of 18 cases. Mod Pathol 11(5): 444–449Google Scholar
  74. Shan L, Nakamura Y, Nakamura M et al. (1998) Somatic mutations of multiple endocrine neoplasia type 1 gene in the sporadic endocrine tumors. Lab Invest 78: 471–475PubMedGoogle Scholar
  75. Simon B, Bartsch D, Rieder H, Joseph K, Rothmund M, Arnold R (1999) Multiple endokrine Neoplasie Typ 1. Dtsch Ärztebl 11: A-698–704, B-600–605, C549–554Google Scholar
  76. Stanley BA, Baker L (1999) The causes of neonatal hypoglycemia. New Engl J Med 340: 1200–1201PubMedCrossRefGoogle Scholar
  77. Stinner B, Kisker O, Zielke A, Rothmund M (1996) Surgical management for carcinoid tumors of small bowel, appendix, colon, and rectum. World J Surg 20: 183–188PubMedCrossRefGoogle Scholar
  78. Thomas PM, Cote GJ, Wohllk N et al. (1995) Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hyperglycemia of infancy. Science 268: 426–429PubMedCrossRefGoogle Scholar
  79. Thomas PM, Wohllk N, Huang E et al. (1996a) Inactivation of the first nucleotide-binding fold of the sulfonylurea recept familial persistent hyperinsulinemic hypoglycemia of infancy. Am J Hum Genet 59: 510–518PubMedGoogle Scholar
  80. Thomas P, Ye Y, Lightner E (1996b) Mutation of the pancreatic islet inward rectifier Kir6. 2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. Hum Mol Genet 5: 1809–1812PubMedCrossRefGoogle Scholar
  81. Trendle MC, Moertel CG, Kvols LK (1996) Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and mailgnant islet cell carcinoma. Cancer 79: 830–834CrossRefGoogle Scholar
  82. Verner JV, Morrison AB (1958) Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med 25: 374–380PubMedCrossRefGoogle Scholar
  83. Walmsley D, Matheson NA, Ewen S, Himsworth RL, Bevan JS (1995) Nesidioblastosis in an elderly patient. Diabet Med 12: 542–545PubMedCrossRefGoogle Scholar
  84. Wang EH, Ebrahimi SA, Wu AY, Kashefi C, Passaro E Jr, Sawicki M (1998) Mutation of the MENIN gene in sporadic pancreatic endocrine tumors. Cancer Res 58: 4417–4420PubMedGoogle Scholar
  85. Whipple AO, Franz UK (1935) Adenoma of islet cells with hyperinsulinism. Am Surg 101: 1299–1335Google Scholar
  86. Zhuang Z, Vortmeyer AO, Pack S et al. (1997) Somatic mutations of the MEN 1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 57: 4682–4686PubMedGoogle Scholar
  87. Zollinger RM, Ellison EH (1955) Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 142: 709–726PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • R. Arnold
  • B. Simon
  • R. Göke

There are no affiliations available

Personalised recommendations